Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells is li...
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells is ...
The treatment’s success in three people raises hopes for mass production of cutting-edge CAR-T therapies.
A study in mouse models of allogeneic stem cell transplantation with donor-derived CD19 chimeric antigen receptor (CAR) T cells for the treatment of relapsed B cell malignancies indicates that T cell exhaustion might have a role in preventing allogeneic reactivity of CD19 CAR T cells. This is ...
proliferative relapsed ALL, the use of donor T cells for CAR T cell manufacturing represents an attractive opportunity to expand the use of CAR T cell therapy in ALL following post-alloHCT relapse. We recently published the results of a phase 1/2 prospective study assessing memory-enriched CD...
Allo-CT†AII0-CT+ IL-2†AIIo-ACT+ IL-2§Total T Cells/kgOtherEvidence for ResponseGVHD Post-Cell TherapyAlive and WellDied (mo post-BMT) + - - 2.1 × 106 - Hematologic response, karyotype: female, PCR Y chrom: negative Grade II >96 - + + - 1.3 × 108 - Progressive disease...
CD19-targeted CAR T cells Long-term outcome of CAR19 T cell therapy for R/R ALL CARs are engineered to bind to a specific antigen leading to activation of the CAR T cells without the dual restriction traditionally conferred by specific T cell receptor and the major histocompatibility complex ...
Mattapally, et al., “Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy,” Journal of American Heart Association, 2018(7):1-13, (Nov. 29, 2018). Meissner, et al., “Genome Editing for Human Gene Therapy...
Production of Universal Anti-Bcma CAR-T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma Chimeric antigen receptor (CAR)-T therapy has recently shown great promise against multiple myeloma (MM) by targeting the B cell maturation antigen (BCMA)....
Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia After Bone Marrow Transplantation: Separation of Graft-Versus-Leukemia Responses From Graft-Versus-Host Disease - ScienceDirect 来自 Elsevier 喜欢 0 阅读量: 18 作者:...